新辅助治疗前后基质肿瘤浸润淋巴细胞在三阴性及HER2阳性乳腺癌中的预测与预后价值
结果显示,低治疗前TILs与较低pCR率相关;在三阴性乳腺癌残留病灶患者中,低治疗前和治疗后TILs均与较短RFS相关。
要点
- 低治疗前TILs与三阴性和HER2阳性乳腺癌较低pCR率相关。
- 三阴性乳腺癌残留病灶中,低治疗前TILs与较短RFS独立相关。
- 低治疗后TILs与较短RFS呈边缘显著关联,TILs变化与RFS无关。
核心结论
- 在三阴性和HER2阳性乳腺癌中,低治疗前TILs肿瘤获得pCR的可能性较低。
- 在三阴性乳腺癌残留病灶患者中,低治疗前和治疗后TILs均与较短RFS相关。
- 结果提示在新辅助治疗后追加治疗时,应考虑TILs信息。
主要发现
- 低治疗前TILs相比中/高TILs与较低pCR率显著相关(三阴性:4.0% vs 43.6%;HER2阳性:26.0% vs 51.9%)。
- 中位随访98个月,在三阴性乳腺癌残留病灶患者中,多因素分析显示低治疗前TILs与较短RFS显著相关(HR=3.844 [1.190-12.421],p=0.024)。
- 低治疗后TILs与较短RFS呈边缘显著关联(HR=2.836 [0.951-8.457],p=0.061)。
- TILs变化与RFS无关;在HER2阳性乳腺癌中,低治疗前TILs与RFS无关。
临床怎么用
- 对于三阴性和HER2阳性乳腺癌,治疗前TILs低提示pCR可能性低,可考虑强化新辅助治疗策略。
- 在三阴性乳腺癌残留病灶患者中,治疗前和治疗后TILs低提示RFS较短,可能需加强术后辅助治疗或随访。
局限性
- 单中心回顾性研究,样本量有限,结论需外部验证。
- HER2阳性乳腺癌中治疗前后TILs与RFS的关联未详细报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Lymphocyte predominant breast cancer (BC) is associated with higher pathological complete response (pCR) rate after neoadjuvant therapy (NAT) and favorable outcome in triple negative breast cancer (TNBC) and HER2+ BC. The predictive and prognostic impact of stromal tumour-infiltrating lymphocytes (TILs) after NAT and the change of TILs before (pre-) and after (post-) NAT are not well studied. We aimed to assess the predictive and prognostic value of pre- and post-NAT TILs, as well as their pharmacodynamics modulation and their change for TNBC and HER2+ BC. MATERIALS AND METHODS: Two-hundred and nine consecutive patients (n = 80 TNBC, n = 129 HER2+ BC) who received NAT between 2001 and 2009 in a single institution were included. We evaluated the association between pre-NAT TILs and pCR, and the association between pre- and post-NAT TILs, as well as their immunodynamics change with relapse-free survival (RFS) for patients with residual disease (RD). RESULTS: Low pre-NAT TILs compared to int/high were significantly associated with lower pCR rate (TNBC: 4.0% vs 43.6%; HER2+ BC: 26.0% vs 51.9%). The median follow-up period was 98 months. In TNBC with RD, low pre-NAT TILs showed significant association with shorter RFS (HR = 3.844 [1.190-12.421], p = 0.024) in multivariate analysis. Low post-NAT TILs showed borderline significant association with shorter RFS (HR = 2.836 [0.951-8.457], p = 0.061). The change in TILs was not associated with RFS. In HER2+ BC, low pre-NAT TILs were not associated with RFS. CONCLUSION: In TN and HER2+ BCs, low pre-NAT TILs tumours had a low likelihood of achieving pCR. In TNBC with RD, both low pre- and post-NAT TILs were associated with shorter RFS. These results suggest that TILs information should be taken into account when additional therapies may be given in the post-neoadjuvant setting.
引用
- Ochi T, Bianchini G, Ando M, et al. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. Eur J Cancer. 2019. PMID: 31302586. doi:10.1016/j.ejca.2019.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。